Home » Key Drug Discovery Articles » SAR156497, an exquisitely selective inhibitor of aurora kinases

SAR156497, an exquisitely selective inhibitor of aurora kinases

Carry JC*†, Clerc F†, Minoux H ‡, Schio L†, Mauger J#, Nair A, Parmantier E#, Le Moigne R†, Delorme C†, Nicolas JP†, Krick A§, Abécassis PY§, Crocq-Stuerga V∥, Pouzieux S‡, Delarbre L‡, Maignan S‡, Bertrand T, Bjergarde K, Ma N, Lachaud S, Guizani H†, Lebel R†, Doerflinger G†, Monget S†, Perron S, Gasse F†, Angouillant-Boniface O†,Filoche-Rommé B†, Murer M⊥, Gontier S⊥, Prévost C⊥, Monteiro ML⊥, Combeau C†.

J Med Chem. 2015 Jan 8;58(1):362-75.

Oncology Drug Discovery, Structure Design Informatics, §Disposition Safety Animal Research, Chemical Development, and Analytical Sciences, Sanofi, 13 Quai Jules Guesde, 94403 Vitry-sur-Seine, France
# Combinatorial Techno Center, Sanofi, 2090 East Innovation Park Drive, Oro Valley, Arizona 85755-1965, United States.

 

Abstract

The Aurora family of serine/threonine kinases is essential for mitosis. Their crucial role in cell cycle regulation and aberrant expression in a broad range of malignancies have been demonstrated and have prompted intensive search for small molecule Aurora inhibitors. Indeed, over 10 of them have reached the clinic as potential anticancer therapies. We report herein the discovery and optimization of a novel series of tricyclic molecules that has led to SAR156497, an exquisitely selective Aurora A, B, and C inhibitor with in vitro and in vivo efficacy. We also provide insights into its mode of binding to its target proteins, which could explain its selectivity.

Go To PubMed

SAR156497